A new approach for prediction of tumor sensitivity to targeted drugs based on functional data
暂无分享,去创建一个
Ranadip Pal | Noah Berlow | Charles Keller | Lara E. Davis | Emma L. Cantor | Bernard Séguin | Noah E. Berlow | R. Pal | C. Keller | B. Séguin | L. Davis
[1] J. Mesirov,et al. Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] Michael B. Elowitz,et al. Erratum: The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability (Proceedings of the National Academy of Sciences of the United States of America (September 30, 2003) 100:20 (11547-11552)) , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[3] E. Hovig,et al. p53 abnormalities in different subtypes of human sarcomas. , 1993, Cancer research.
[4] C. Sawyers,et al. Targeted cancer therapy , 2004, Nature.
[5] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[6] John F. Karpovich,et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2008 .
[7] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[8] Mark R. Green,et al. Targeting targeted therapy. , 2004, The New England journal of medicine.
[9] V. Wee Yong,et al. Involvement of p 21 Waf 1 / Cip 1 in Protein Kinase C Alpha-Induced Cell Cycle Progression , 2000 .
[10] John C. Lee,et al. ERK Pathway Mediates the Activation of Cdk2 in IGF‐1–Induced Proliferation of Human Osteosarcoma MG‐63 Cells , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] P. Zarrinkar,et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.
[12] A. Richmond,et al. Mouse xenograft models vs GEM models for human cancer therapeutics , 2008, Disease Models & Mechanisms.
[13] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[14] Philippe Robin,et al. ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. , 2002, American journal of physiology. Cell physiology.
[15] E. Solary,et al. AC 220 is a uniquely potent and selective inhibitor of FLT 3 for the treatment of acute myeloid leukemia ( AML ) , 2009 .
[16] David Benavidez,et al. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma , 2010, International journal of cancer.
[17] Aniruddha Datta,et al. Robust Intervention in Probabilistic Boolean Networks , 2007, ACC.
[18] A. Datta,et al. Bayesian Robustness in the Control of Gene Regulatory Networks , 2007 .
[19] J. Sklar,et al. Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies , 2011, Cancer journal.
[20] M. Scheffner,et al. Ubiquitin, E6-AP, and their role in p53 inactivation. , 1998, Pharmacology & therapeutics.
[21] Josef Kittler,et al. Floating search methods in feature selection , 1994, Pattern Recognit. Lett..
[22] B. Druker,et al. Molecularly targeted therapy: have the floodgates opened? , 2004, The oncologist.
[23] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[24] V. Wee Yong,et al. Involvement of p21Waf1/Cip1 in Protein Kinase C Alpha-Induced Cell Cycle Progression , 2000, Molecular and Cellular Biology.
[25] Renzo Boldorini,et al. Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.
[26] B. Druker,et al. RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.
[27] David M. Thomas,et al. Molecular pathogenesis of osteosarcoma. , 2007, DNA and cell biology.
[28] Levi Garraway,et al. High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes , 2012, Cancer.
[29] Ranadip Pal,et al. A Kinase Inhibition Map Approach for Tumor Sensitivity Prediction and Combination Therapy Design for Targeted Drugs , 2011, Pacific Symposium on Biocomputing.
[30] Ranadip Pal,et al. Anticancer drug sensitivity analysis: An integrated approach applied to Erlotinib sensitivity prediction in the CCLE database , 2012, Proceedings 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS).
[31] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[32] Adam A. Margolin,et al. Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia , 2010 .
[33] Julio Saez-Rodriguez,et al. Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data , 2009, PLoS Comput. Biol..
[34] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[35] Aniruddha Datta,et al. Bayesian Robustness in the Control of Gene Regulatory Networks , 2007, IEEE Transactions on Signal Processing.
[36] Howard L McLeod,et al. PI3K/Akt/mTOR pathway as a target for cancer therapy , 2005, Anti-cancer drugs.
[37] Stuart A. Kauffman,et al. The origins of order , 1993 .
[38] B. Druker,et al. Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.
[39] P. Picci,et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma , 1999, International journal of cancer.
[40] Howard A. Fine,et al. Predicting in vitro drug sensitivity using Random Forests , 2011, Bioinform..
[41] Michael B. Elowitz,et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability , 2003, Proceedings of the National Academy of Sciences of the United States of America.